334 related articles for article (PubMed ID: 35321560)
21. Immune checkpoint inhibitor-related myasthenia gravis, myositis and myocarditis: a triad but not at the same time?
Cooksley T; Weaver J; McNamara M; Lorigan P
QJM; 2024 Jun; 117(5):373-374. PubMed ID: 38229249
[No Abstract] [Full Text] [Related]
22. Immune checkpoint inhibitors induced side effects of the peripheral nervous system.
Hundsberger T; Schreiner B; Roth P
Curr Opin Neurol; 2023 Oct; 36(5):427-431. PubMed ID: 37639489
[TBL] [Abstract][Full Text] [Related]
23. Pembrolizumab-Induced Fatal Myasthenia, Myocarditis, and Myositis in a Patient with Metastatic Melanoma: Autopsy, Histological, and Immunohistochemical Findings-A Case Report and Literature Review.
Giovannini E; Bonasoni MP; D'Aleo M; Tamagnini I; Tudini M; Fais P; Pelotti S
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446095
[TBL] [Abstract][Full Text] [Related]
24. Immune Checkpoint Inhibitor-Associated Myositis: A Distinct Form of Inflammatory Myopathy.
Saygin D; Ghosh N; Reid P
J Clin Rheumatol; 2022 Oct; 28(7):367-373. PubMed ID: 35696731
[TBL] [Abstract][Full Text] [Related]
25. Clinical characteristics, treatment and outcome of nivolumab-induced myasthenia gravis.
Wang C; Zeng H; Fang W; Song L
Invest New Drugs; 2023 Apr; 41(2):333-339. PubMed ID: 36988830
[TBL] [Abstract][Full Text] [Related]
26. Myocarditis and myositis/myasthenia gravis overlap syndrome induced by immune checkpoint inhibitor followed by esophageal hiatal hernia: A case report and review of the literature.
Yin B; Xiao J; Wang X; Li X; Guan Y; Chen J; Han P; Li K; Wang J
Front Med (Lausanne); 2022; 9():950801. PubMed ID: 36457566
[TBL] [Abstract][Full Text] [Related]
27. Immune Checkpoint Inhibitor-induced Myositis.
Jayan A; Mammen AL; Suarez-Almazor ME
Rheum Dis Clin North Am; 2024 May; 50(2):281-290. PubMed ID: 38670726
[TBL] [Abstract][Full Text] [Related]
28. Incidence and Distinct Features of Immune Checkpoint Inhibitor-Related Myositis From Idiopathic Inflammatory Myositis: A Single-Center Experience With Systematic Literature Review and Meta-Analysis.
Hamada N; Maeda A; Takase-Minegishi K; Kirino Y; Sugiyama Y; Namkoong H; Horita N; Yoshimi R; Nakajima H;
Front Immunol; 2021; 12():803410. PubMed ID: 34938300
[TBL] [Abstract][Full Text] [Related]
29. Neurological adverse events of immune checkpoint inhibitors: An update of clinical presentations, diagnosis, and management.
Farina A; Villagrán-García M; Honnorat J
Rev Neurol (Paris); 2023 Jun; 179(5):506-515. PubMed ID: 36934022
[TBL] [Abstract][Full Text] [Related]
30. Clinical spectrum of neuromuscular complications after immune checkpoint inhibition.
Puwanant A; Isfort M; Lacomis D; Živković SA
Neuromuscul Disord; 2019 Feb; 29(2):127-133. PubMed ID: 30638612
[TBL] [Abstract][Full Text] [Related]
31. Nivolumab-induced Myositis and Myocarditis with Positive Anti-titin Antibody and Anti-voltage-gated Potassium Channel Kv1.4 Antibody.
Ono R; Iwai Y; Yamazaki T; Takahashi H; Hori Y; Fukushima K; Saotome T
Intern Med; 2022 Oct; 61(19):2973-2979. PubMed ID: 35314545
[TBL] [Abstract][Full Text] [Related]
32. Consider Myocarditis When Patients Treated with Immune Checkpoint Inhibitors Present with Ocular Symptoms.
Rhee JY; Torun N; Neilan TG; Guidon AC
Oncologist; 2022 May; 27(5):e402-e405. PubMed ID: 35348772
[TBL] [Abstract][Full Text] [Related]
33. Immune checkpoint inhibitor-associated myositis and myasthenia gravis overlap: Understanding the diversity in a case series.
Wong EYT; Yong MH; Yong KP; Tan EH; Toh CK; Kanesvaran R; Takano A; Ng QS
Asia Pac J Clin Oncol; 2021 Oct; 17(5):e262-e267. PubMed ID: 32985078
[TBL] [Abstract][Full Text] [Related]
34. Myasthenia Gravis Induced by Immune Checkpoint Inhibitors: An Emerging Neurotoxicity in Neuro-Oncology Practice: Case Series.
Marco C; Simó M; Alemany M; Casasnovas C; Domínguez R; Vilariño N; Calvo M; Martín-Liberal J; Brenes J; Sabater-Riera J; Bruna J; Velasco R
J Clin Med; 2022 Dec; 12(1):. PubMed ID: 36614930
[TBL] [Abstract][Full Text] [Related]
35. Immune Checkpoint Inhibitor-Induced Myocarditis With Concurrent Myasthenia Gravis.
Kuniyoshi J; Huang R; Choi H; Bernas M; Techasatian W; Nishimura Y
Can J Cardiol; 2023 Nov; 39(11):1646-1648. PubMed ID: 37330137
[No Abstract] [Full Text] [Related]
36. Immune Checkpoint Inhibitor-Induced Myositis/Myocarditis with Myasthenia Gravis-like Misleading Presentation: A Case Series in Intensive Care Unit.
Deharo F; Carvelli J; Cautela J; Garcia M; Sarles C; Maues de Paula A; Bourenne J; Gainnier M; Bichon A
J Clin Med; 2022 Sep; 11(19):. PubMed ID: 36233479
[TBL] [Abstract][Full Text] [Related]
37. Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians.
Raschi E; Rossi S; De Giglio A; Fusaroli M; Burgazzi F; Rinaldi R; Potena L
Drug Saf; 2023 Sep; 46(9):819-833. PubMed ID: 37341925
[TBL] [Abstract][Full Text] [Related]
38. Immune Checkpoint Inhibition-Related Myasthenia-Myositis-Myocarditis Responsive to Complement Blockade.
Nelke C; Pawlitzki M; Kerkhoff R; Schroeter CB; Aktas O; Neuen-Jacob E; Polzin A; Meuth SG; Ruck T
Neurol Neuroimmunol Neuroinflamm; 2024 Jan; 11(1):. PubMed ID: 37884388
[TBL] [Abstract][Full Text] [Related]
39. Immune checkpoint inhibitor-induced myocarditis with myasthenia gravis overlap syndrome: A case report and literature review.
Gao L; Li X; Guo Z; Tang L; Peng J; Liu B
Medicine (Baltimore); 2022 Dec; 101(49):e32240. PubMed ID: 36626474
[TBL] [Abstract][Full Text] [Related]
40. Neurological adverse events related to immune-checkpoint inhibitors in Spain: a retrospective cohort study.
Fonseca E; Cabrera-Maqueda JM; Ruiz-García R; Naranjo L; Diaz-Pedroche C; Velasco R; Macias-Gómez A; Milisenda JC; Muñoz-Farjas E; Pascual-Goñi E; Gállego Perez-Larraya J; Saiz A; Dalmau J; Blanco Y; Graus F; Martinez-Hernandez E;
Lancet Neurol; 2023 Dec; 22(12):1150-1159. PubMed ID: 37977714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]